Privi Speciality Chemicals Limited has informed the Exchange regarding Board meeting held on Jun 14, 2025.
PRIVISCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Privi Speciality Chemicals, at its June 14, 2025 meeting, decided to scrap its earlier plan to raise up to ₹1,000 crore via a Qualified Institutions Placement (QIP), citing improved business performance and sufficient internal cash accruals to fund capital expenditure. Separately, the Board approved a scheme of amalgamation to merge Privi Fine Sciences Private Limited (PFSPL, a related party) and Privi Biotechnologies Private Limited (PBPL, a wholly owned subsidiary) into Privi Speciality Chemicals. The merger is aimed at consolidating its aroma chemicals, green science, and biotechnology businesses under one roof. As per the approved share exchange ratio, every 7,000 equity shares of PFSPL (face value ₹10) will be swapped for 7.9897 equity shares of Privi Speciality Chemicals. Crucially, unlike the earlier acquisition plan from June 2024, this merger involves no cash outflow. Since PFSPL is owned largely by the promoter group (CMD Mahesh Babani holds 87.59%), this is classified as a material related party transaction and will require shareholder approval. The scheme also needs NCLT, SEBI, and stock exchange clearances.
Net positive for shareholders — the QIP cancellation avoids equity dilution, and the all-stock merger brings in complementary green science and biotech assets without any cash payout. Post-merger promoter holding rises marginally from 74.05% to 74.67%, with public shareholding dipping slightly to 25.33%. Watch for NCLT and shareholder approval timelines.